Inaktiver Wert

Avanir Pharmaceuticals Inc Aktie

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Avanir Pharmaceuticals : Announces Appointment of Rohan Palekar as President and Chief Executive Officer	20.01.16
Avanir Pharmaceuticals : Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease	10.12.15
Avanir Pharmaceuticals : Announces JAMA Publication of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in Patients with Alzheimer's Disease	22.09.15
Avanir Pharmaceuticals : Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026	11.08.15
Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference	23.07.15

Manager	Titel	Alter	Seit
Dan Dalton CMP	Compliance Officer	-	01.06.16
Kelly Parker IRO	Public Communications Contact	-	01.06.15
Aneta Ferguson LAW	General Counsel	-	01.01.15

Aufsichtsräte	Titel	Alter	Seit
Donald Hayden CHM	Chairman	68	-
Robert McQuade BRD	Director/Board Member	67	-
Thomas DesRosier BRD	Director/Board Member	69	-

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 Mrd.
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 Mrd.
ARGENX SE	+1,69 %	22,15 Mrd.
BIONTECH SE	-17,37 %	21,02 Mrd.
GENMAB A/S	-9,30 %	18,15 Mrd.
WUXI APPTEC CO., LTD.	-41,01 %	16,74 Mrd.
BEIGENE, LTD.	-14,85 %	16,05 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 Mrd.
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 Mrd.